



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 114184

Title: Peroxiredoxin 1, pyroptosis, and the emerging frontier in colorectal cancer therapy

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 08200937

Position: Peer Reviewer

Academic degree and professional title: Associate Professor, MD, PhD

Reviewer's Country/Territory: China

Author's Country/Territory: India

Manuscript submission date: 2025-09-12

Reviewer chosen by: Jia-Lin Zhang

Reviewer accepted review: 2025-09-19 01:29

Reviewer performed review: 2025-09-24 23:49

Review time: 5 Days and 22 Hours

Content to be reviewed	Does the manuscript's content fall within the scope of the journal? Yes Is there any Key Word that is not included in the manuscript title? Yes Does the Abstract contain the contents of each part of the manuscript (IMRaD)? Yes Are the Key Words complete? Yes Is the content of the Introduction adequate? Yes Is the content of the Materials and Methods complete? Yes
-------------------------------	--



Baishideng Publishing Group

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

Is the description of the experiments clear and complete? **Yes**

Are the experimental data presented in the manuscript's biostatistics content reliable? **Not Applicable**

Are the experimental data of the Results true and reliable? **Not Applicable**

Are the quality and resolution of the images up to standard? **Not Applicable**

Do the selection and design of the figures and tables follow the principles of necessity and clarity? **Not Applicable**

Is there any duplication between various parts of the manuscript and between the main text and the content presented in the figures and tables? **Not Applicable**

Are the figures and tables numbered consecutively in the order in which they appear in the manuscript? **Not Applicable**

Is the content of the Discussion reasonable? **Not Applicable**

Is the Conclusion reasonable? **Yes**

Are all references necessary and reasonable? **Yes**

Do authors omit important references? **No**

Are all references related to the topic of the manuscript? **Yes**

Do authors only cite their own earlier publications? **No**

Is the manuscript's text correct, concise, and clear? **Yes**

Will the manuscript's content be of interest to readers? **Yes**

Are additional experiments needed for the study? **No**



	Does the research scope comply with ethics? Not Applicable Do authors' affiliations correspond to the content of the manuscript? Yes
Scientific quality	Grade B (Very good)
Novelty of this manuscript	Grade B (Very Good)
Creativity or innovation of this manuscript	Grade B (Very Good)
Scientific significance of the conclusion in this manuscript	Grade A (Excellent)
Language quality	Grade A (Excellent)
Does this manuscript describe a study of the existing knowledge system?	No
Does this manuscript report a revolutionary innovation?	No
Does this manuscript report an unconventional innovation?	No
Conclusion	Accept
Re-review	Yes
Peer-reviewer statements	Peer-Review: Anonymous
	Conflicts-of-Interest: No
Are your review comments generated by AI tools?	No

SPECIFIC COMMENTS TO AUTHORS

This editorial summarised the study performed by He et al. (World J Gastroenterol 2025; 31(36): 111557) which identifies a novel mechanism by which peroxiredoxin 1 (Prdx1) inhibits CRC progression through induction of pyroptosis, a pro-inflammatory form of



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

programmed cell death. Traditionally viewed as an intracellular antioxidant that protects tumors from oxidative stress, Prdx1 assumes a paradoxical immunogenic role when released extracellularly as a damage-associated molecular pattern (DAMP). Using patient samples, recombinant protein assays, and murine xenograft models, the authors demonstrate that Prdx1 activates the NLRP3 inflammasome/Caspase-1/GSDMD pathway, triggering membrane pore formation, tumor cell lysis, and release of IL-1 β /IL-18. This cascade not only halts tumor proliferation, invasion, and migration but may also enhance anti-tumor immune surveillance. The study's strengths include rigorous mechanistic validation, clinical cohort data, inhibitor-based causal proof, and in vivo confirmation. However, questions remain regarding the upstream receptor for Prdx1, heterogeneity across CRC subtypes, and the balance between therapeutic benefit and inflammatory toxicity. By establishing Prdx1-induced pyroptosis as a driver of tumor suppression, this work advances a promising paradigm in CRC therapy, linking cell death to immune activation and pointing toward future biomarker-driven, pyroptosis-based interventions.

This editorial provides a concise summary of the article and effectively identifies specific shortcomings, such as the absence of clarity regarding the cell-surface receptor mediating Prdx1 recognition in CRC. While activation of the NLRP3 inflammasome and downstream Caspase-1/GSDMD is firmly established, the initial trigger remains undefined. Past literature implicates TLR4 as a plausible mediator in macrophages, but it remains unproven in epithelial cancer cells. Identifying this receptor will be essential to design targeted strategies that selectively exploit Prdx1's pyroptotic function. Another limitation is the restricted spectrum of tested cell lines. Only three CRC models were studied, with robust effects observed in RKO and SW480 cells but not in HCT116. This editorial also looks forward to the prospects of this research field, and I believe it can effectively help readers understand the article and related issues.



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 114184

Title: Peroxiredoxin 1, pyroptosis, and the emerging frontier in colorectal cancer therapy

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 08215565

Position: Peer Reviewer

Academic degree and professional title: Associate Chief Physician, MD

Reviewer's Country/Territory: China

Author's Country/Territory: India

Manuscript submission date: 2025-09-12

Reviewer chosen by: Jia-Lin Zhang

Reviewer accepted review: 2025-09-25 00:55

Reviewer performed review: 2025-10-03 06:31

Review time: 8 Days and 5 Hours

Content to be reviewed	Does the manuscript's content fall within the scope of the journal? Yes Is there any Key Word that is not included in the manuscript title? No Do authors' affiliations correspond to the content of the manuscript? Yes Does the Abstract contain the contents of each part of the manuscript (IMRaD)? Yes Are the Key Words complete? Yes Is the content of the Introduction adequate? Yes
-------------------------------	---



Baishideng Publishing Group

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

Is the content of the Materials and Methods complete?

Not Applicable

Is the description of the experiments clear and complete? **Not Applicable**

Are the experimental data presented in the manuscript's biostatistics content reliable? **Not Applicable**

Are the experimental data of the Results true and reliable? **Not Applicable**

Are the quality and resolution of the images up to standard? **Not Applicable**

Do the selection and design of the figures and tables follow the principles of necessity and clarity? **Not Applicable**

Is there any duplication between various parts of the manuscript and between the main text and the content presented in the figures and tables? **No**

Are the figures and tables numbered consecutively in the order in which they appear in the manuscript? **Not Applicable**

Is the content of the Discussion reasonable? **Yes**

Is the Conclusion reasonable? **Yes**

Are all references necessary and reasonable? **Yes**

Do authors omit important references? **No**

Are all references related to the topic of the manuscript? **Yes**

Do authors only cite their own earlier publications? **No**

Is the manuscript's text correct, concise, and clear? **Yes**

Will the manuscript's content be of interest to readers?
Yes



	Are additional experiments needed for the study? No Does the research scope comply with ethics? Not Applicable
Scientific quality	Grade A (Excellent)
Novelty of this manuscript	Grade B (Very Good)
Creativity or innovation of this manuscript	Grade B (Very Good)
Scientific significance of the conclusion in this manuscript	Grade B (Very Good)
Language quality	Grade B (Very good)
Does this manuscript describe a study of the existing knowledge system?	Yes
Does this manuscript report a revolutionary innovation?	No
Does this manuscript report an unconventional innovation?	No
Conclusion	Minor revision
Re-review	Yes
Peer-reviewer statements	Peer-Review: Anonymous
	Conflicts-of-Interest: No
Are your review comments generated by AI tools?	No

SPECIFIC COMMENTS TO AUTHORS

This editorial provides a clear, logically structured, and well-written commentary that offers a comprehensive and insightful interpretation of the study by He et al. The author adeptly captures the dual role of Prdx1 in cancer including intracellular antioxidant protection versus extracellular DAMP inducing pyroptosis, and effectively



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

contextualizes it within the complexity of the tumor immune microenvironment, highlighting the study's translational potential and challenges. The manuscript possesses significant academic value and is thought-provoking.

This manuscript possesses several notable strengths: it addresses a timely and significant topic at the forefront of pyroptosis and cancer immunotherapy, grounded in timely, clinically relevant research. The author delivers a critical and in-depth analysis that moves beyond summary to rigorously evaluate mechanistic insights, experimental models, and clinical correlations. Its structure is clear and logical, seamlessly guiding the reader from background to future directions. The writing is precise, especially in explaining complex pathways like NLRP3/Caspase-1/GSDMD with admirable clarity. Most importantly, the editorial demonstrates sharp critical thinking by pinpointing key limitations, such as the unidentified receptor and model heterogeneity, and proposing concrete, actionable steps for future investigation.

It is recommended for publication after minor revisions, as detailed below:

1. Some sections could be more concise. For instance, the comparison of different cell death modalities in the "PYROPTOSIS" section could be slightly condensed to avoid repetition. Correspondingly, suggestions in the "FUTURE DIRECTIONS" could be more specific. For example, the idea of combining rPrdx1 with immune checkpoint blockade should mention specific targets, such as PD-1/PD-L1 inhibitors, to provide a more concrete research direction.
2. Consistency in reference formatting requires attention. For example, the year "202M4" in Reference 8 should be corrected to "2024". Journal name abbreviations should be unified according to PubMed standards.
3. The discussion could be enhanced by briefly mentioning other well-known DAMPs (e.g., HMGB1, ATP) and their roles in CRC when introducing Prdx1 as a DAMP, thus strengthening contextual links. The "CONCLUSION" could further emphasize the



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

potential of "precision pyroptosis therapy" in personalized medicine, resonating with the "biomarker-driven" theme.

4. The manuscript alternates between "rPrdx1" and "recombinant Prdx1". It is recommended to consistently use the abbreviated form "rPrdx1" throughout the text for uniformity.



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 114184

Title: Peroxiredoxin 1, pyroptosis, and the emerging frontier in colorectal cancer therapy

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 08215565

Position: Peer Reviewer

Academic degree and professional title: Associate Chief Physician, MD

Reviewer's Country/Territory: China

Author's Country/Territory: India

Manuscript submission date: 2025-09-12

Reviewer chosen by: Jing-Jie Wang

Reviewer accepted review: 2025-10-24 05:59

Reviewer performed review: 2025-10-25 12:58

Review time: 1 Day and 6 Hours

Content to be reviewed	Does the manuscript's content fall within the scope of the journal? Yes Is there any Key Word that is not included in the manuscript title? No Do authors' affiliations correspond to the content of the manuscript? Yes Does the Abstract contain the contents of each part of the manuscript (IMRaD)? Yes Are the Key Words complete? Yes Is the content of the Introduction adequate? Yes
-------------------------------	---



Baishideng Publishing Group

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

Is the content of the Materials and Methods complete?

Not Applicable

Is the description of the experiments clear and complete? **Not Applicable**

Are the experimental data presented in the manuscript's biostatistics content reliable? **Not Applicable**

Are the experimental data of the Results true and reliable? **Not Applicable**

Are the quality and resolution of the images up to standard? **Not Applicable**

Do the selection and design of the figures and tables follow the principles of necessity and clarity? **Not Applicable**

Is there any duplication between various parts of the manuscript and between the main text and the content presented in the figures and tables? **Not Applicable**

Are the figures and tables numbered consecutively in the order in which they appear in the manuscript? **Not Applicable**

Is the content of the Discussion reasonable? **Yes**

Is the Conclusion reasonable? **Yes**

Are all references necessary and reasonable? **Yes**

Do authors omit important references? **No**

Are all references related to the topic of the manuscript? **Yes**

Do authors only cite their own earlier publications? **No**

Is the manuscript's text correct, concise, and clear? **Yes**

Will the manuscript's content be of interest to readers?
Yes



	Are additional experiments needed for the study? No Does the research scope comply with ethics? Not Applicable
Scientific quality	Grade A (Excellent)
Novelty of this manuscript	Grade B (Very Good)
Creativity or innovation of this manuscript	Grade B (Very Good)
Scientific significance of the conclusion in this manuscript	Grade B (Very Good)
Language quality	Grade B (Very good)
Does this manuscript describe a study of the existing knowledge system?	Yes
Does this manuscript report a revolutionary innovation?	No
Does this manuscript report an unconventional innovation?	No
Conclusion	Minor revision
Peer-reviewer statements	Peer-Review: Anonymous
	Conflicts-of-Interest: No
Are your review comments generated by AI tools?	No

SPECIFIC COMMENTS TO AUTHORS

This editorial provides a comprehensive, insightful, and critical commentary on the study by He et al. concerning Peroxiredoxin 1 (Prdx1) inhibiting colorectal cancer through the induction of pyroptosis. The author clearly elucidates the dual role of Prdx1 in cancer (intracellular antioxidant vs. extracellular DAMP) and offers a detailed analysis of the mechanistic findings, strengths, and limitations of the He et al. study, while also



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

proposing forward-looking future research directions. The topic is cutting-edge, the logical structure is sound, the language is fluent, and the manuscript holds significant academic value and is thought-provoking. Following the previous round of revisions, the author has adequately addressed and incorporated the reviewers' suggestions: the "PYROPTOSIS" section has been condensed to avoid repetition in comparing different cell death modalities; reference formatting errors (e.g., the year "202M4") have been corrected, with a commitment to standardizing journal abbreviations; a paragraph discussing other well-known DAMPs like HMGB1 and ATP and their roles in CRC has been added to the "STRENGTHS AND LIMITATIONS" section, strengthening contextual links; and "recombinant Prdx1" has been consistently replaced with "rPrdx1" to maintain terminology uniformity.

Specific details requiring the author's further attention before final submission primarily involve formatting norms are as follows:

1. Manuscript title: According to Item 3 of the Checklist for Authors, except for the first word, all other words should be in lowercase. In the current title "Peroxi**redoxin** 1, **Pyroptosis**, and the **Emerging Frontier** in **Colorectal Cancer Therapy**", the words "Pyroptosis", "Emerging", "Frontier", "Colorectal", "Cancer", and "Therapy" are capitalized. It is recommended to revise it to: "Peroxi**redoxin** 1, **pyroptosis**, and the **emerging frontier** in **colorectal cancer therapy**".
2. Author contributions: According to Item 8 of the Checklist for Authors and the Science Editor's comments, the format of the 'Author contributions' description needs adjustment. The format "full family (sur)name, followed by abbreviated first and middle names" should be used. For example, "Dharmendra Kumar Maurya" should be written as "Maurya DK". It is recommended to revise to: "Maurya DK performed the review of literature and wrote the editorial."
3. Key words: According to Item 13 of the Checklist for Authors, 5-10 keywords are



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
https://www.wjgnet.com

recommended. Currently, there are only 4. Consider adding 1-2 more, such as "NLRP3 inflammasome" or "Immunogenic cell death", to better cover the core content of the article.

4. References: The core article discussed in this editorial (He et al. World J Gastroenterol 2025; 31(36): 111557) needs to be formally added to the reference list and cited with the corresponding reference number in the main text (e.g., in the Introduction, Discussion sections). Additionally, as per Item 23 of the Checklist for Authors, use the "Auto-Analyser" tool for final proofreading and formatting of all references to ensure accurate PMID and DOI information, complete author lists, and fully unified formatting.

5. Other formatting items: According to the Checklist for Authors, ensure that the format of sections like "Received/Revised" dates, the Open-Access statement, and the Specialty type complies with the journal's requirements.